Michael Buschle
Direktor/Vorstandsmitglied bei VICORE PHARMA HOLDING AB
Aktive Positionen von Michael Buschle
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VICORE PHARMA HOLDING AB | Direktor/Vorstandsmitglied | 01.01.2023 | - |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Private Equity Investor | 01.01.2017 | - |
Karriereverlauf von Michael Buschle
Ehemalige bekannte Positionen von Michael Buschle
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Y-MABS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.10.2017 | 11.12.2018 |
Independent Dir/Board Member | 01.10.2017 | 11.12.2018 | |
GLENMARK PHARMACEUTICALS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 23.01.2012 | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Technik-/Wissenschafts-/F&E-Leiter | 03.12.1997 | - |
Gründer | 03.12.1997 | - |
Statistik
International
Österreich | 2 |
Indien | 2 |
Schweiz | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 2 |
Founder | 1 |
Sektoral
Health Technology | 5 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
GLENMARK PHARMACEUTICALS LIMITED | Health Technology |
Y-MABS THERAPEUTICS, INC. | Health Technology |
VICORE PHARMA HOLDING AB | Health Technology |
Private Unternehmen | 2 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
- Börse
- Insiders
- Michael Buschle
- Erfahrung